Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT0596 in R/R Multiple Myeloma and Plasma Cell Leukemia
NCT06730256Phase 1Recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Jul 2025
- Primary completion
- Jan 2027
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CT0596 in multiple myeloma (MM) and plasma cell leukemia (PCL), sponsored by First Affiliated Hospital of Soochow University. Primary endpoints: Adverse Events (AE) after CT0596 infusion at 12 months and Maximum tolerated dose and/or dose range at 12 months. Started Jul 2025; status: recruiting.
02
Drugs
CT0596
03
Conditions
multiple myeloma (MM)plasma cell leukemia (PCL)
Beyond the preview
Go deeper on NCT06730256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06730256.